Cargando…
Idiosyncratic drug‐induced liver injury: A short review
Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain qual...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678908/ https://www.ncbi.nlm.nih.gov/pubmed/29404475 http://dx.doi.org/10.1002/hep4.1064 |
_version_ | 1783277534759092224 |
---|---|
author | Yamashita, Yo‐ichi Imai, Katsunori Mima, Kosuke Nakagawa, Shigeki Hashimoto, Daisuke Chikamoto, Akira Baba, Hideo |
author_facet | Yamashita, Yo‐ichi Imai, Katsunori Mima, Kosuke Nakagawa, Shigeki Hashimoto, Daisuke Chikamoto, Akira Baba, Hideo |
author_sort | Yamashita, Yo‐ichi |
collection | PubMed |
description | Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI. Antimicrobials, central nervous system agents, and herbal and dietary supplements are the most common causes of iDILI in developed countries. iDILI is still a diagnosis of exclusion, and thus careful history taking and thorough work‐ups for competing etiologies, such as acute viral hepatitis, autoimmune hepatitis, and others, are essential. The pathogenesis of iDILI is not clear and includes a mix of host reactions, drug metabolites, and environmental factors. Immediate cessation of the suspected offending drug is key to preventing or minimizing progressive damage. No definitive therapies for iDILI are available, and the treatments remain largely supportive. (Hepatology Communications 2017;1:494–500) |
format | Online Article Text |
id | pubmed-5678908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56789082018-02-05 Idiosyncratic drug‐induced liver injury: A short review Yamashita, Yo‐ichi Imai, Katsunori Mima, Kosuke Nakagawa, Shigeki Hashimoto, Daisuke Chikamoto, Akira Baba, Hideo Hepatol Commun Review Articles Idiosyncratic drug‐induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI. Antimicrobials, central nervous system agents, and herbal and dietary supplements are the most common causes of iDILI in developed countries. iDILI is still a diagnosis of exclusion, and thus careful history taking and thorough work‐ups for competing etiologies, such as acute viral hepatitis, autoimmune hepatitis, and others, are essential. The pathogenesis of iDILI is not clear and includes a mix of host reactions, drug metabolites, and environmental factors. Immediate cessation of the suspected offending drug is key to preventing or minimizing progressive damage. No definitive therapies for iDILI are available, and the treatments remain largely supportive. (Hepatology Communications 2017;1:494–500) John Wiley and Sons Inc. 2017-06-28 /pmc/articles/PMC5678908/ /pubmed/29404475 http://dx.doi.org/10.1002/hep4.1064 Text en © 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Yamashita, Yo‐ichi Imai, Katsunori Mima, Kosuke Nakagawa, Shigeki Hashimoto, Daisuke Chikamoto, Akira Baba, Hideo Idiosyncratic drug‐induced liver injury: A short review |
title | Idiosyncratic drug‐induced liver injury: A short review |
title_full | Idiosyncratic drug‐induced liver injury: A short review |
title_fullStr | Idiosyncratic drug‐induced liver injury: A short review |
title_full_unstemmed | Idiosyncratic drug‐induced liver injury: A short review |
title_short | Idiosyncratic drug‐induced liver injury: A short review |
title_sort | idiosyncratic drug‐induced liver injury: a short review |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678908/ https://www.ncbi.nlm.nih.gov/pubmed/29404475 http://dx.doi.org/10.1002/hep4.1064 |
work_keys_str_mv | AT yamashitayoichi idiosyncraticdruginducedliverinjuryashortreview AT imaikatsunori idiosyncraticdruginducedliverinjuryashortreview AT mimakosuke idiosyncraticdruginducedliverinjuryashortreview AT nakagawashigeki idiosyncraticdruginducedliverinjuryashortreview AT hashimotodaisuke idiosyncraticdruginducedliverinjuryashortreview AT chikamotoakira idiosyncraticdruginducedliverinjuryashortreview AT babahideo idiosyncraticdruginducedliverinjuryashortreview |